Published in J Hepatol on April 25, 2009
Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene (2013) 1.55
The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it. Endocr Relat Cancer (2013) 0.96
Complex roles of filamin-A mediated cytoskeleton network in cancer progression. Cell Biosci (2013) 0.95
Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J Gastrointest Oncol (2012) 0.93
Identification of cellular targets in human intrahepatic cholangiocarcinoma using laser microdissection and accurate mass and time tag proteomics. Mol Cell Proteomics (2010) 0.90
Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer (2013) 0.90
Hypoxia-induced and calpain-dependent cleavage of filamin A regulates the hypoxic response. Proc Natl Acad Sci U S A (2014) 0.87
Targeting filamin A reduces K-RAS-induced lung adenocarcinomas and endothelial response to tumor growth in mice. Mol Cancer (2012) 0.85
Three are better than one: plasminogen receptors as cancer theranostic targets. Exp Hematol Oncol (2013) 0.84
ERCC1 Can Be a Prognostic Factor in Hilar Cholangiocarcinoma and Extrahepatic Bile Duct Cancer, But Not in Intrahepatic Cholangiocarcinoma. Cancer Res Treat (2013) 0.80
Targeting filamin B induces tumor growth and metastasis via enhanced activity of matrix metalloproteinase-9 and secretion of VEGF-A. Oncogenesis (2014) 0.79
Disease control with sunitinib in advanced intrahepatic cholangiocarcinoma resistant to gemcitabine-oxaliplatin chemotherapy. World J Hepatol (2015) 0.78
Binding of pro-prion to filamin A: by design or an unfortunate blunder. Oncogene (2010) 0.78
Expression of hepatocyte markers in mass-forming peripheral and periductal-infiltrating hilar intrahepatic cholangiocarcinomas. Oncol Lett (2011) 0.78
Expression of keratin 20 and its clinicopathological significance in intrahepatic cholangiocarcinoma. Oncol Lett (2012) 0.76
Unravelling a new mechanism linking actin polymerization and gene transcription. Nucleus (2016) 0.75
The case for immune-based approaches in biliary tract carcinoma. Hepatology (2016) 0.75
Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. Int J Mol Sci (2017) 0.75
International network of cancer genome projects. Nature (2010) 20.35
Early liver transplantation for severe alcoholic hepatitis. N Engl J Med (2011) 8.50
Identification of cells initiating human melanomas. Nature (2008) 8.28
Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology (2010) 8.11
Electric-field control of local ferromagnetism using a magnetoelectric multiferroic. Nat Mater (2008) 7.23
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol (2008) 5.93
Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology (2006) 5.46
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (2007) 4.73
Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol (2006) 4.42
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology (2007) 3.61
Simplified staging for hepatocellular carcinoma. J Clin Oncol (2002) 3.48
The "50-50 criteria" on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy. Ann Surg (2005) 3.46
Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg (2003) 3.16
Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation. J Hepatol (2006) 3.14
Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes (2006) 3.06
Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology (2009) 2.97
A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82
Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg (2006) 2.70
Sources of variability in histological scoring of chronic viral hepatitis. Hepatology (2005) 2.64
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol (2005) 2.62
Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol (2011) 2.59
Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol (2010) 2.57
Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology (2003) 2.57
A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. Transplantation (2006) 2.55
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Fibrosis in human adipose tissue: composition, distribution, and link with lipid metabolism and fat mass loss. Diabetes (2010) 2.46
Hemorrhage after pancreaticoduodenectomy: when is surgery still indicated? Am J Surg (2007) 2.44
Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol (2010) 2.43
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl (2005) 2.43
Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol (2005) 2.38
Changing trends in malignant transformation of hepatocellular adenoma. Gut (2011) 2.28
Benefit of laparoscopy for rectal resection in patients operated simultaneously for synchronous liver metastases: preliminary experience. Surgery (2008) 2.25
Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol (2008) 2.22
[Clinical practice guidelines on the use of liver biopsy]. Gastroenterol Clin Biol (2002) 2.22
Prospective comparison of spleen and liver stiffness by using shear-wave and transient elastography for detection of portal hypertension in cirrhosis. Radiology (2014) 2.22
Right portal vein ligation: a new planned two-step all-surgical approach for complete resection of primary gastrointestinal tumors with multiple bilateral liver metastases. J Am Coll Surg (2003) 2.20
Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int (2008) 2.19
Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology (2011) 2.14
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol (2007) 2.08
Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology (2004) 2.08
Risk factors for Enterobacteriaceae bacteremia after liver transplantation. Transpl Int (2008) 2.06
Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res (2013) 2.05
Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg (2003) 2.03
Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med (2011) 2.03
Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology (2009) 2.00
Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. Ann Surg (2013) 1.98
Diagnostic criteria and severity assessment of acute cholecystitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg (2007) 1.98
Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology (2006) 1.97
IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol (2011) 1.97
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology (2008) 1.95
Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol (2011) 1.94
Ischemic complications after pancreaticoduodenectomy: incidence, prevention, and management. Ann Surg (2009) 1.89
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection. Liver Int (2011) 1.84
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol (2013) 1.84
Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res (2010) 1.83
CD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol (2008) 1.82
Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl (2010) 1.81
CMV drives clonal expansion of NKG2C+ NK cells expressing self-specific KIRs in chronic hepatitis patients. Eur J Immunol (2011) 1.81
Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology (2014) 1.81
Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology (2009) 1.79
Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery (2002) 1.76
The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int (2009) 1.76
Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl (2008) 1.75
Major hepatectomy for the treatment of complex bile duct injury. Ann Surg (2008) 1.74
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71
Risk factors of fibrosis in alcohol-induced liver disease. Hepatology (2002) 1.70
A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology (2009) 1.70
Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol (2012) 1.66
Liver biopsy: the best, not the gold standard. J Hepatol (2008) 1.65
Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology (2012) 1.64
Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int (2011) 1.64
Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology (2015) 1.62
VEGFR-1 expressed by malignant melanoma-initiating cells is required for tumor growth. Cancer Res (2011) 1.62
Reappraisal of central pancreatectomy a 12-year single-center experience. JAMA Surg (2014) 1.62
Management of hepatic vascular diseases. J Hepatol (2012) 1.61
Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol (2009) 1.58
Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg (2007) 1.58